成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >AZD0780
AZD0780
  • AZD0780

AZD0780 NEW

Price $93 $228 $372
Package 1mg 5mg 10mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-19

Product Details

Product Name: AZD0780 CAS No.: 2455427-91-3
Purity: 99.74% Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

NameAZD0780
DescriptionAZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone.
StorageShipping with blue ice.
Solubility InformationDMSO : 50 mg/mL (120.65 mM)
KeywordsAZD 0780 | AZD0780 | EX-A 6975 | EX-A-6975 | AZD-0780
Related Compound LibrariesBioactive Compound Library | Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$/
Anhui Ruihan Technology Co., Ltd
2023-08-21
  • Since: 2011-01-07
  • Address: 36?Washington?Street, Wellesley?Hills
INQUIRY